- Report
- September 2023
- 274 Pages
Global
From €3285EUR$3,600USD£2,801GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €456EUR$500USD£389GBP
Vyvanse is a central nervous system (CNS) drug used to treat attention deficit hyperactivity disorder (ADHD) and binge eating disorder (BED). It is a stimulant medication that works by increasing the levels of dopamine and norepinephrine in the brain. Vyvanse is available in both immediate-release and extended-release formulations. The extended-release formulation is designed to provide a longer duration of action.
Vyvanse is a popular treatment option for ADHD and BED due to its efficacy and safety profile. It is generally well-tolerated and has few side effects. Common side effects include insomnia, decreased appetite, and headaches.
The Vyvanse market is highly competitive, with several major pharmaceutical companies offering the drug. These companies include Shire, Teva Pharmaceuticals, and Actavis. Other companies, such as Mylan and Impax Laboratories, also offer generic versions of the drug. Show Less Read more